FDA Grants Orphan Drug Designation for Stromedix's STX-100
Posted on: Friday, 15 August 2008, 09:00 CDT
Stromedix has announced that its lead clinical candidate STX-100 has been granted orphan drug status by the FDA for the treatment of chronic allograft nephropathy.
Chronic allograft nephropathy, also known as chronic allograft dysfunction, is a fibrotic condition that is a cause of kidney transplant failure.
STX-100 is a humanized monoclonal antibody licensed in 2007 from Biogen Idec. Stromedix initiated a Phase I clinical trial of STX-100 in early 2008.
Orphan drug status confers seven years of market exclusivity following FDA approval as well as certain tax advantages to companies that take on the challenge of developing life-saving drugs for small patient populations.
Michael Gilman, CEO of Stromedix, said: "There is a clear medical need for therapies that prolong graft function in kidney transplant patients and that more broadly inhibit fibrosis in other clinical settings. We have made rapid progress on STX-100 since obtaining the program from Biogen Idec last year. This action by the FDA should facilitate the development of this drug for transplant patients."
Source: Datamonitor
Related Articles
- U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
- Stromedix Receives Orphan Drug Designation for STX-100 in Chronic Allograft Nephropathy
- FDA OKs YM Pain Drug for Clinical Trials
- US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP
- Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
- FDA Approves New Diabetes Drug
- Panel Recommends FDA OK for Hepatitis Drug
- FDA Grants Encysive Orphan Drug Designation For Thelin
- FDA Backs Anti-Nausea Drug for Some
 |
 |
User Comments (0)
RSS Feeds